Role of 3-Hydroxy Fatty Acid-Induced Hepatic Lipotoxicity in Acute Fatty Liver of Pregnancy

Total Page:16

File Type:pdf, Size:1020Kb

Role of 3-Hydroxy Fatty Acid-Induced Hepatic Lipotoxicity in Acute Fatty Liver of Pregnancy International Journal of Molecular Sciences Review Role of 3-Hydroxy Fatty Acid-Induced Hepatic Lipotoxicity in Acute Fatty Liver of Pregnancy Sathish Kumar Natarajan 1 ID and Jamal A. Ibdah 2,3,4,* 1 Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583-0806, USA; [email protected] 2 Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, USA 3 Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA 4 Harry S. Truman Memorial Veterans Medical Center, Columbia, MO 65201, USA * Correspondence: [email protected]; Tel.: +1-573-882-7349; Fax: +1-573-884-4595 Received: 1 January 2018; Accepted: 16 January 2018; Published: 22 January 2018 Abstract: Acute fatty liver of pregnancy (AFLP), a catastrophic illness for both the mother and the unborn offspring, develops in the last trimester of pregnancy with significant maternal and perinatal mortality. AFLP is also recognized as an obstetric and medical emergency. Maternal AFLP is highly associated with a fetal homozygous mutation (1528G>C) in the gene that encodes for mitochondrial long-chain hydroxy acyl-CoA dehydrogenase (LCHAD). The mutation in LCHAD results in the accumulation of 3-hydroxy fatty acids, such as 3-hydroxy myristic acid, 3-hydroxy palmitic acid and 3-hydroxy dicarboxylic acid in the placenta, which are then shunted to the maternal circulation leading to the development of acute liver injury observed in patients with AFLP. In this review, we will discuss the mechanistic role of increased 3-hydroxy fatty acid in causing lipotoxicity to the liver and in inducing oxidative stress, mitochondrial dysfunction and hepatocyte lipoapoptosis. Further, we also review the role of 3-hydroxy fatty acids in causing placental damage, pancreatic islet β-cell glucolipotoxicity, brain damage, and retinal epithelial cells lipoapoptosis in patients with LCHAD deficiency. Keywords: acute fatty liver of pregnancy; 3-hydroxy fatty acids; lipoapoptosis; fatty acid oxidation 1. Fatty Acid Oxidation Humans have three major types of fatty acid oxidation pathways that feeds high energy reducing equivalents to the mitochondria for the generation of ATP. Mitochondrial β-oxidation, peroxisome β-oxidation, and microsomal !-oxidation pathways are the three types of oxidation for long chain fatty acids. 1.1. Mitochondrial Fatty Acid Oxidation Mitochondrial long chain fatty acid β-oxidation is the predominant cellular oxidation pathway with the production of acetyl-Coenzyme A (CoA), which feeds into the tricarboxylic acid (TCA) cycle for the high-energy ATP production via the mitochondrial electron transport chain. Fatty acids are acylated and activated by fatty acyl-CoA synthetase in the outer mitochondrial membrane. Carnitine acyl transferase I converts acyl-CoA into fatty acyl carnitine, which is translocated across the inner mitochondrial membrane by carnitine translocase. Carnitine acyl transferase II in the inner mitochondrial membrane catalyzes the formation of fatty acyl-CoA for the initiation of the β-oxidation pathway [1–4]. Classic mitochondrial fatty acid β-oxidation involves a four-step process: dehydrogenation, hydration, dehydrogenation and thiolytic cleavage (Figure1). Acyl-CoA dehydrogenase initiates β-oxidation by catalyzing the first dehydrogenation step, forms a double Int. J. Mol. Sci. 2018, 19, 322; doi:10.3390/ijms19010322 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2018, 19, 322 2 of 17 Int. J. Mol. Sci. 2018, 19, x 2 of 16 bond, and converts fatty acyl-CoA into trans-enoyl-CoA. The next three steps in the β-oxidation of longbond, chainand converts fatty acids fatty acyl-CoA are catalyzed into trans-enoyl-CoA. by mitochondrial The tri-functionalnext three steps protein in the β (MTP).-oxidation MTP of is a complexlong chain heterooctamer fatty acids are protein catalyzed attached by mitochondrial to the inner tri-functional mitochondrial protein membrane (MTP). MTP with is a 4 complexα-subunits andheterooctamer 4β-subunits encodedprotein attached by the HADHAto the innerand mitochondrialHADHB gene, membrane respectively. with The4α-subunitsα-subunit and contains 4β- longsubunits chain enoyl-CoAencoded by the hydratase HADHA activity and HADHB in its gene, amino-terminal respectively. domain,The α-subunit while contains long chain long chain hydroxy acyl-CoAenoyl-CoA dehydrogenase hydratase activity (LCHAD) in its activity amino-terminal resides at domain, the carboxyl-terminal while long chain domain. hydroxy The acyl-CoAβ-subunit containsdehydrogenase the long chain (LCHAD) 2-ketoacyl-CoA activity resides thiolase at the activity, carboxyl-terminal which catalyzes domain. the fourthThe β-subunit step in βcontains-oxidation cycle.the Enoyl-CoAlong chain 2-ketoacyl-CoA hydratase in thethiolaseα-subunit activity, catalyzes which catalyzes the conversion the fourth of step enoyl-CoA in β-oxidation to 3-hydroxy cycle. acyl-CoA.Enoyl-CoA Next, hydratase 3-hydroxy in the acyl-CoA α-subunit is catalyzes oxidized the to conversion form 3-keto of enoyl-CoA acyl-CoA to by 3-hydroxy the enzyme acyl-CoA. LCHAD. Next, 3-hydroxy acyl-CoA is oxidized to form 3-keto acyl-CoA by the enzyme LCHAD. The final step The final step of β-oxidation is catalyzed by thiolase, which generates acetyl-CoA and a fatty acyl-CoA. of β-oxidation is catalyzed by thiolase, which generates acetyl-CoA and a fatty acyl-CoA. The cycle The cycle of β-oxidation proceeds with a shorter fatty acyl-CoA for the continuous energy demand of β-oxidation proceeds with a shorter fatty acyl-CoA for the continuous energy demand and supply and supply of acetyl-CoA. Pediatric defects in mitochondrial fatty acid oxidation (FAO) are recessively of acetyl-CoA. Pediatric defects in mitochondrial fatty acid oxidation (FAO) are recessively inherited inheritedand have and emerged have emerged as an important as an importantgroup of inborn group errors of inborn of metabolism errors of with metabolism clinical significance. with clinical significance.Affected patients Affected with patients mitochondrial with mitochondrial FAO defects FAO usually defects present usually in the present first inyear the of first life yearwith of a life withReye’s-like a Reye’s-like syndrome, syndrome, cardiomyopathy, cardiomyopathy, and andneur neuro-myopathy.o-myopathy. Death Death quic quicklykly ensue ensue unless unless the the disorderdisorder is rapidly is rapidly recognized recognized and and treated. treated. FigureFigure 1. Mitochondrial1. Mitochondrial fatty fatty acid acidβ β-oxidation-oxidation pathway.pathway. Classical Classical ββ-oxidation-oxidation pathway pathway involves involves dehydrogenasedehydrogenase by by acyl-CoA acyl-CoA dehydrogenase dehydrogenase andand hydration,hydration, dehydrogenation dehydrogenation and and thiolyic thiolyic cleavage cleavage is catalyzedis catalyzed by by the the mitochondrial mitochondrial trifunctional trifunctional proteinprotein (MTP, (MTP, highlighted highlighted in in red red color). color). MTP MTP consists consists of enoyl-CoAof enoyl-CoA hydratase, hydratase, hydroxy hydroxy acyl-CoA acyl-CoA dehydrog dehydrogenaseenase and thiolase and thiolase activity. activity. The straight The arrows straight arrowsrepresent represent products products and bent and arrows bent arrowsrepresent represent the involvement the involvement of co-factor of in co-factorthis enzyme in thiscatalyzed enzyme catalyzedreaction. reaction. 1.2. Peroxisomal and Microsomal Fatty Acid Oxidation 1.2. Peroxisomal and Microsomal Fatty Acid Oxidation In the event of defective mitochondrial β-oxidation due to a mutation in the β-oxidation enzymes,In the event long of chain defective fatty mitochondrialacids can be channeledβ-oxidation to peroxisomal due to a mutation β-oxidation in the andβ-oxidation microsomal enzymes, ω- longoxidation chain fatty [5,6]. acids Unlike can mitochondrial be channeled tofatty peroxisomal acid oxidation,β-oxidation peroxisomal and microsomalβ-oxidation !is -oxidationnot coupled [5 ,6]. Unlikewith mitochondrialthe mitochondrial fatty electron acid oxidation,transport ch peroxisomalain and ATP generation.β-oxidation Increased is not coupledperoxisomal with β- the mitochondrialoxidation would electron increase transport the production chain and of hydrog ATP generation.en peroxide as Increased a byproduct peroxisomal of the peroxisomalβ-oxidation wouldacyl-CoA increase oxidase, the production a rate-limiting of hydrogenenzyme and peroxide first step as of a peroxisomal byproduct ofβ-oxidation. the peroxisomal The rest acyl-CoAof the Int. J. Mol. Sci. 2018, 19, 322 3 of 17 oxidase, a rate-limiting enzyme and first step of peroxisomal β-oxidation. The rest of the peroxisomal β-oxidation pathway is similar to the mitochondrial β-oxidation pathway with the exception of the presence of a peroxisomal bifunctional protein, which contains an N-terminal peroxisomal enoyl-CoA hydratase and a C-terminal region that contains 3-hydroxy acyl-CoA dehydrogenase activity. Increased reactive oxygen species from the peroxisomal β-oxidation can lead to redox imbalance, mitochondrial dysfunction and cellular injury [7]. Further, accumulated fatty acids and 3-hydroxy fatty acids can also be shunted to the endoplasmic reticulum for microsomal !-oxidation. In the liver, peroxisome proliferator-activator receptor (PPAR)-α transcriptionally regulates genes that encodes for both peroxisomal β-oxidation and microsomal !-oxidation enzymes [6]. Enhanced microsomal !-oxidation of fatty acids and 3-hydroxy fatty
Recommended publications
  • Diapositiva 1
    ns 10 A Unmethylated C Methylated ) 8 Normal Normal Tissue Cervix Esophagus 4 cervical esophageal a.u. * *** * *** ( 6 TargetID MAPINFO Position Ca-Ski HeLa SW756 tissue COLO-680N KYSE-180 OACM 5.1C tissue cg04255070 22851591 TSS1500 0.896 0.070 0.082 0.060 0.613 0.622 0.075 0.020 2 (log2) 4 cg01593340 22851587 TSS1500 0.826 0.055 0.051 0.110 0.518 0.518 0.034 0.040 cg16113692 22851502 TSS200 0.964 0.073 0.072 0.030 0.625 0.785 0.018 0.010 2 0 cg26918510 22851422 TSS200 0.985 0.019 0.000 0.000 0.711 0.961 0.010 0.060 expression cg26821579 22851416 TSS200 0.988 0.083 0.058 0.000 0.387 0.955 0.021 0.050 TRMT12 mRNA Expression mRNA TRMT12 0 cg01129966 22851401 TSS200 0.933 0.039 0.077 0.020 0.815 0.963 0.078 0.010 -2 cg25421615 22851383 TSS200 0.958 0.033 0.006 0.000 0.447 0.971 0.037 0.020 mRNA cg17953636 22851321 1stExon 0.816 0.092 0.099 0.080 0.889 0.750 0.136 0.030 -4 Methylated SVIP Unmethylated SVIP relative expression (a.u.) expression relative SVIP D Cervix Esophagus HNC Meth ) HNC Unmeth Cervix Meth 3.0 *** Cervix Unmeth *** Esophagus Meth a.u. ( 2.5 CaCaEsophagus-Ski-Ski Unmeth COLO-680N Haematological Meth TSS B TSS Haematological Unmeth 2.0 -244 bp +104 bp 244 bp +104 bp 1.5 ** * expression -SVIP 1.0 HeLa KYSE-180 HeLa TSS TSS 0.5 -ACTB 244 bp +104 bp - 244 bp +104 bp mRNA 0.0 HeLa SW756 Ca-Ski SW756 SW756 OACM 5.1C TSS KYSE-180 TSS COLO-680NOACM 5.1 C - 244 bp +104 bp 244 bp +104 bp E ) 3.0 * Ca-Ski COLO-680N WT TSS TSS 2.0 a.u.
    [Show full text]
  • Altered Expression and Function of Mitochondrial Я-Oxidation Enzymes
    0031-3998/01/5001-0083 PEDIATRIC RESEARCH Vol. 50, No. 1, 2001 Copyright © 2001 International Pediatric Research Foundation, Inc. Printed in U.S.A. Altered Expression and Function of Mitochondrial ␤-Oxidation Enzymes in Juvenile Intrauterine-Growth-Retarded Rat Skeletal Muscle ROBERT H. LANE, DAVID E. KELLEY, VLADIMIR H. RITOV, ANNA E. TSIRKA, AND ELISA M. GRUETZMACHER Department of Pediatrics, UCLA School of Medicine, Mattel Children’s Hospital at UCLA, Los Angeles, California 90095, U.S.A. [R.H.L.]; and Departments of Internal Medicine [D.E.K., V.H.R.] and Pediatrics [R.H.L., A.E.T., E.M.G.], University of Pittsburgh School of Medicine, Magee-Womens Research Institute, Pittsburgh, Pennsylvania 15213, U.S.A. ABSTRACT Uteroplacental insufficiency and subsequent intrauterine creased in IUGR skeletal muscle mitochondria, and isocitrate growth retardation (IUGR) affects postnatal metabolism. In ju- dehydrogenase activity was unchanged. Interestingly, skeletal venile rats, IUGR alters skeletal muscle mitochondrial gene muscle triglycerides were significantly increased in IUGR skel- expression and reduces mitochondrial NADϩ/NADH ratios, both etal muscle. We conclude that uteroplacental insufficiency alters of which affect ␤-oxidation flux. We therefore hypothesized that IUGR skeletal muscle mitochondrial lipid metabolism, and we gene expression and function of mitochondrial ␤-oxidation en- speculate that the changes observed in this study play a role in zymes would be altered in juvenile IUGR skeletal muscle. To test the long-term morbidity associated with IUGR. (Pediatr Res 50: this hypothesis, mRNA levels of five key mitochondrial enzymes 83–90, 2001) (carnitine palmitoyltransferase I, trifunctional protein of ␤-oxi- dation, uncoupling protein-3, isocitrate dehydrogenase, and mi- Abbreviations tochondrial malate dehydrogenase) and intramuscular triglycer- CPTI, carnitine palmitoyltransferase I ides were quantified in 21-d-old (preweaning) IUGR and control IUGR, intrauterine growth retardation rat skeletal muscle.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Role of De Novo Cholesterol Synthesis Enzymes in Cancer Jie Yang1,2, Lihua Wang1,2, Renbing Jia1,2
    Journal of Cancer 2020, Vol. 11 1761 Ivyspring International Publisher Journal of Cancer 2020; 11(7): 1761-1767. doi: 10.7150/jca.38598 Review Role of de novo cholesterol synthesis enzymes in cancer Jie Yang1,2, Lihua Wang1,2, Renbing Jia1,2 1. Department of Ophthalmology, Ninth People’s Hospital of Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China. Corresponding authors: Renbing Jia, [email protected] and Lihua Wang, [email protected]. Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Zhi Zao Ju Road, Shanghai 200011, China © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.07.21; Accepted: 2019.11.30; Published: 2020.01.17 Abstract Despite extensive research in the cancer field, cancer remains one of the most prevalent diseases. There is an urgent need to identify specific targets that are safe and effective for the treatment of cancer. In recent years, cancer metabolism has come into the spotlight in cancer research. Lipid metabolism, especially cholesterol metabolism, plays a critical role in membrane synthesis as well as lipid signaling in cancer. This review focuses on the contribution of the de novo cholesterol synthesis pathway to tumorigenesis, cancer progression and metastasis. In conclusion, cholesterol metabolism could be an effective target for novel anticancer treatment. Key words: metabolic reprogramming, de novo cholesterol synthesis, cancer progress Introduction Over the past few decades, numerous published that cholesterol plays a critical role in cancer studies have focused on cancer cell metabolism and progression15-19.
    [Show full text]
  • Colorectal Cancer and Omega Hydroxylases
    1 The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance Abdo Alnabulsi1,2, Rebecca Swan1, Beatriz Cash2, Ayham Alnabulsi2, Graeme I Murray1 1Pathology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB25, 2ZD, UK. 2Vertebrate Antibodies, Zoology Building, Tillydrone Avenue, Aberdeen, AB24 2TZ, UK. Address correspondence to: Professor Graeme I Murray Email [email protected] Phone: +44(0)1224 553794 Fax: +44(0)1224 663002 Running title: omega hydroxylases and colorectal cancer 2 Abstract Background: Colorectal cancer is a common malignancy and one of the leading causes of cancer related deaths. The metabolism of omega fatty acids has been implicated in tumour growth and metastasis. Methods: This study has characterised the expression of omega fatty acid metabolising enzymes CYP4A11, CYP4F11, CYP4V2 and CYP4Z1 using monoclonal antibodies we have developed. Immunohistochemistry was performed on a tissue microarray containing 650 primary colorectal cancers, 285 lymph node metastasis and 50 normal colonic mucosa. Results: The differential expression of CYP4A11 and CYP4F11 showed a strong association with survival in both the whole patient cohort (HR=1.203, 95% CI=1.092-1.324, χ2=14.968, p=0.001) and in mismatch repair proficient tumours (HR=1.276, 95% CI=1.095-1.488, χ2=9.988, p=0.007). Multivariate analysis revealed that the differential expression of CYP4A11 and CYP4F11 was independently prognostic in both the whole patient cohort (p = 0.019) and in mismatch repair proficient tumours (p=0.046). Conclusions: A significant and independent association has been identified between overall survival and the differential expression of CYP4A11 and CYP4F11 in the whole patient cohort and in mismatch repair proficient tumours.
    [Show full text]
  • RESEARCH COMMUNICATION HADHA Is a Potential Predictor Of
    HADHA is a Potential Predictor of the Response to Platinum-based Chemotherapy RESEARCH COMMUNICATION HADHA is a Potential Predictor of Response to Platinum-based Chemotherapy for Lung Cancer Taihei Kageyama1, Ryo Nagashio1, 2, Shinichiro Ryuge 3, Toshihide Matsumoto1,5, Akira Iyoda4, Yukitoshi Satoh4, Noriyuki Masuda3, Shi-Xu Jiang5, Makoto Saegusa5, Yuichi Sato1, 2* Abstract To identify a cisplatin resistance predictor to reduce or prevent unnecessary side effects, we firstly established four cisplatin-resistant sub-lines and compared their protein profiles with cisplatin-sensitive parent lung cancer cell lines using two-dimensional gel electrophoresis. Between the cisplatin-resistant and -sensitive cells, a total of 359 protein spots were differently expressed (>1.5 fold), and 217 proteins (83.0%) were identified. We focused on a mitochondrial protein, hydroxyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hydratase alpha subunit (HADHA), which was increased in all cisplatin-resistant cells. Furthermore, pre- treated biopsy specimens taken from patients who showed resistance to platinum-based treatment showed a significantly higher positive rate for HADHA in all cases (p=0.00367), including non-small cell lung carcinomas (p=0.002), small-cell lung carcinomas (p=0.038), and adenocarcinomas (p=0.008). These results suggest that the expression of HADHA may be a useful marker to predict resistance to platinum-based chemotherapy in patients with lung cancer. Keywords: Cisplatin - HADHA - lung cancer - two-dimensional gel electrophoresis Asian Pacific J Cancer Prev, 12, 3457-3463 Introduction cisplatin resistance rose due to a decrease of blood flow in the tumor and increased DNA repair (Stewart, 2007), Lung cancer is the leading cause of cancer-related the mechanisms underlying cisplatin resistance have not death in the world, and the five-year overall survival rate yet been clarified, and an effective cisplatin resistance is still below 16% (Jemal et al., 2009).
    [Show full text]
  • Health Effects Support Document for Perfluorooctanoic Acid (PFOA)
    United States Office of Water EPA 822-R-16-003 Environmental Protection Mail Code 4304T May 2016 Agency Health Effects Support Document for Perfluorooctanoic Acid (PFOA) Perfluorooctanoic Acid – May 2016 i Health Effects Support Document for Perfluorooctanoic Acid (PFOA) U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 EPA Document Number: 822-R-16-003 May 2016 Perfluorooctanoic Acid – May 2016 ii BACKGROUND The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the U.S. Environmental Protection Agency (EPA) to periodically publish a list of unregulated chemical contaminants known or anticipated to occur in public water systems and that may require regulation under SDWA. The SDWA also requires the Agency to make regulatory determinations on at least five contaminants on the Contaminant Candidate List (CCL) every 5 years. For each contaminant on the CCL, before EPA makes a regulatory determination, the Agency needs to obtain sufficient data to conduct analyses on the extent to which the contaminant occurs and the risk it poses to populations via drinking water. Ultimately, this information will assist the Agency in determining the most appropriate course of action in relation to the contaminant (e.g., developing a regulation to control it in drinking water, developing guidance, or deciding not to regulate it). The PFOA health assessment was initiated by the Office of Water, Office of Science and Technology in 2009. The draft Health Effects Support Document for Perfluoroctanoic Acid (PFOA) was completed in 2013 and released for public comment in February 2014.
    [Show full text]
  • (LCHAD) Deficiency / Mitochondrial Trifunctional Protein (MTF) Deficiency
    Long chain acyl-CoA dehydrogenase (LCHAD) deficiency / Mitochondrial trifunctional protein (MTF) deficiency Contact details Introduction Regional Genetics Service Long chain acyl-CoA dehydrogenase (LCHAD) deficiency / mitochondrial trifunctional Levels 4-6, Barclay House protein (MTF) deficiency is an autosomal recessive disorder of mitochondrial beta- 37 Queen Square oxidation of fatty acids. The mitochondrial trifunctional protein is composed of 4 alpha London, WC1N 3BH and 4 beta subunits, which are encoded by the HADHA and HADHB genes, respectively. It is characterized by early-onset cardiomyopathy, hypoglycemia, T +44 (0) 20 7762 6888 neuropathy, and pigmentary retinopathy, and sudden death. There is also an infantile F +44 (0) 20 7813 8578 onset form with a hepatic Reye-like syndrome, and a late-adolescent onset form with primarily a skeletal myopathy. Tandem mass spectrometry of organic acids in urine, Samples required and carnitines in blood spots, allows the diagnosis to be unequivocally determined. An 5ml venous blood in plastic EDTA additional clinical complication can occur in the pregnant mothers of affected fetuses; bottles (>1ml from neonates) they may experience maternal acute fatty liver of pregnancy (AFLP) syndrome or Prenatal testing must be arranged hypertension/haemolysis, elevated liver enzymes and low platelets (HELLP) in advance, through a Clinical syndrome. Genetics department if possible. The genes encoding the HADHA and HADHB subunits are located on chromosome Amniotic fluid or CV samples 2p23.3. The pathogenic
    [Show full text]
  • Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
    cancers Review Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives 1, 1, 1 2 1 Laurence Pellerin y, Lorry Carrié y , Carine Dufau , Laurence Nieto , Bruno Ségui , 1,3 1, , 1, , Thierry Levade , Joëlle Riond * z and Nathalie Andrieu-Abadie * z 1 Centre de Recherches en Cancérologie de Toulouse, Equipe Labellisée Fondation ARC, Université Fédérale de Toulouse Midi-Pyrénées, Université Toulouse III Paul-Sabatier, Inserm 1037, 2 avenue Hubert Curien, tgrCS 53717, 31037 Toulouse CEDEX 1, France; [email protected] (L.P.); [email protected] (L.C.); [email protected] (C.D.); [email protected] (B.S.); [email protected] (T.L.) 2 Institut de Pharmacologie et de Biologie Structurale, CNRS, Université Toulouse III Paul-Sabatier, UMR 5089, 205 Route de Narbonne, 31400 Toulouse, France; [email protected] 3 Laboratoire de Biochimie Métabolique, CHU Toulouse, 31059 Toulouse, France * Correspondence: [email protected] (J.R.); [email protected] (N.A.-A.); Tel.: +33-582-7416-20 (J.R.) These authors contributed equally to this work. y These authors jointly supervised this work. z Received: 15 September 2020; Accepted: 23 October 2020; Published: 27 October 2020 Simple Summary: Melanoma is a devastating skin cancer characterized by an impressive metabolic plasticity. Melanoma cells are able to adapt to the tumor microenvironment by using a variety of fuels that contribute to tumor growth and progression. In this review, the authors summarize the contribution of the lipid metabolic network in melanoma plasticity and aggressiveness, with a particular attention to specific lipid classes such as glycerophospholipids, sphingolipids, sterols and eicosanoids.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain
    1 Review 2 Clinical Implications of 20-Hydroxyeicosatetraenoic 3 Acid in the Kidney, Liver, Lung and Brain: An 4 Emerging Therapeutic Target 5 Osama H. Elshenawy 1, Sherif M. Shoieb 1, Anwar Mohamed 1,2 and Ayman O.S. El-Kadi 1,* 6 1 Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton T6G 2E1, AB, Canada; 7 [email protected] (O.H.E.); [email protected] (S.M.S.); [email protected] (A.M.) 8 2 Department of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of 9 Medicine and Health Sciences, Dubai, United Arab Emirates 10 * Correspondence: [email protected]; Tel.: 780-492-3071; Fax: 780-492-1217 11 Academic Editor: Kishor M. Wasan 12 Received: 12 January 2017; Accepted: 15 February 2017; Published: 20 February 2017 13 Abstract: Cytochrome P450-mediated metabolism of arachidonic acid (AA) is an important 14 pathway for the formation of eicosanoids. The ω-hydroxylation of AA generates significant levels 15 of 20-hydroxyeicosatetraenoic acid (20-HETE) in various tissues. In the current review, we discussed 16 the role of 20-HETE in the kidney, liver, lung, and brain during physiological and 17 pathophysiological states. Moreover, we discussed the role of 20-HETE in tumor formation, 18 metabolic syndrome and diabetes. In the kidney, 20-HETE is involved in modulation of 19 preglomerular vascular tone and tubular ion transport. Furthermore, 20-HETE is involved in renal 20 ischemia/reperfusion (I/R) injury and polycystic kidney diseases. The role of 20-HETE in the liver is 21 not clearly understood although it represents 50%–75% of liver CYP-dependent AA metabolism, 22 and it is associated with liver cirrhotic ascites.
    [Show full text]